ReviewCell & bioscience2023
Roles of bile acids signaling in neuromodulation under physiological and pathological conditions.
Review in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Cross-sectional and longitudinal associations of circulating bile acids and dementia: a systematic review.GeroScience · 2026Pooled it
- Taurochenodeoxycholic acid alleviates MPPIBRO neuroscience reports · 2026Article
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- From Dysbiosis to Blood-Brain Barrier Disruption: The Metabolite-Mediated Gut-Brain Axis in Alzheimer's Disease.Molecular neurobiology · 2026Review
- Improving the Outcome of Brain-Injured Patients by Non-Continuous Feeding to Prevent Dysbiosis.Nutrients · 2026Review
- Ursodeoxycholic acid mitigates cerebral ischemia/reperfusion injury by inhibiting thrombin-induced lipid peroxidation through activation of ALDH3A1.Redox biology · 2026Article
- Microbiota-gut-brain axis and bile acids-driven neuromodulation.Neural regeneration research · 2026Article
- Bile acids in Alzheimer's disease: a double-edged sword in gut-liver-brain signaling and neurodegeneration.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Imatinib-Induced Changes in Anxiety-Like Behaviors are Associated With Prefrontal Cortical Metabolic Remodeling in Mice.Alpha psychiatry · 2026Article
- Gut Microbiota-Targeted Nutrition for Healthy Aging: Mechanistic Roles of Polyphenols and Dietary Fiber in Geroscience.Nutrients · 2026Review
- Limosilactobacillus reuteri Alleviates Parkinson's Disease by Regulating CDCA Secretion.Probiotics and antimicrobial proteins · 2026Article
- Bile Acid Dysregulation in Parkinson's Disease: Longitudinal Changes and Altered Metabolic Interactions.Biomolecules · 2026Article
- Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.Current obesity reports · 2026Review
- The Role of Microbiome-Associated Metabolites and Their Clinical Implications in Traumatic Brain Injury: A Scoping Review.Neurocritical care · 2026Review
- Epigenetic regulation and posttranslational modifications of FXR: underlying mechanisms and implications in digestive diseases.Acta pharmacologica Sinica · 2026Review
- Liver-nervous system axis: pathways, dysregulation, and translational perspectives.Journal of neuroinflammation · 2026Review
- Article
- The Gut-Reproduction-Oral-Immune Axis: Microbial Dysbiosis as a Shared Driver in Polycystic Ovary Syndrome and Endometriosis.Current microbiology · 2026Review
- A polygenetic rat model of divergent aerobic capacity reveals a liver-brain interaction impacting Alzheimer's disease-like phenotypes.The Journal of physiology · 2026Article
- Bile acid signaling, metabolism, and aging.Liver research (Beijing, China) · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
Bile acids (BA) are important physiological molecules not only mediating nutrients absorption and metabolism in peripheral tissues, but exerting neuromodulation effect in the central nerve system (CNS). The catabolism of cholesterol to BA occurs predominantly in the liver by the classical and alternative pathways, or in the brain initiated by the neuronal-specific enzyme CYP46A1 mediated pathway. Circulating BA could cross the blood brain barrier (BBB) and reach the CNS through passive diffusion or BA transporters. Brain BA might trigger direct signal through activating membrane and nucleus receptors or affecting activation of neurotransmitter receptors. Peripheral BA may also provide the indirect signal to the CNS via farnesoid X receptor (FXR) dependent fibroblast growth factor 15/19 (FGF15/19) pathway or takeda G protein coupled receptor 5 (TGR5) dependent glucagon-like peptide-1 (GLP-1) pathway. Under pathological conditions, alterations in BA metabolites have been discovered as potential pathogenic contributors in multiple neurological disorders. Attractively, hydrophilic ursodeoxycholic acid (UDCA), especially tauroursodeoxycholic acid (TUDCA) can exert neuroprotective roles by attenuating neuroinflammation, apoptosis, oxidative or endoplasmic reticulum stress, which provides promising therapeutic effects for treatment of neurological diseases. This review summarizes recent findings highlighting the metabolism, crosstalk between brain and periphery, and neurological functions of BA to elucidate the important role of BA signaling in the brain under both physiological and pathological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.